Provides Quick Symptom Relief and Long Lasting Results for Individuals Who Suffer From the Chronic Skin Condition
Barrier Therapeutics, Inc. (NASDAQ: BTRX)
announced today the introduction of Xolegel CorePak(TM) for the treatment
of seborrheic dermatitis. Now, patients with this chronic skin condition
need only one prescription to get quick itch relief and to safely manage
the overall condition long term.
The two products in Xolegel CorePak are new Xebcort(TM) Gel, a 1%
hydrocortisone gel, and Xolegel® (ketoconazole, USP) Gel, 2%. Xebcort Gel
provides quick symptom relief and is presented as a 0.8 ounce tube designed
for short term use to relieve itch. Xolegel CorePak contains 45 grams of
Xolegel Gel provided in three 15 gram tubes. In a long-term safety trial
with Xolegel Gel, patients remained symptom free for up to 8 weeks
post-treatment.
"By providing the hydrocortisone and ketoconazole gels separately in one
prescription, Xolegel CorePak encourages patients to comply with their
physician's recommendations to better manage this chronic and common
inflammatory skin condition," explained Al Altomari, Chief Executive
Officer of Barrier Therapeutics.
More About the Xolegel Family of Products
With the addition of Xolegel CorePak, there is now a family of Xolegel
products available to treat the variety of seborrheic dermatitis patient
types.
Xolegel Gel is a cosmetically elegant treatment which offers powerful
relief for seborrheic dermatitis of the face and body in immunocompetent
adults and children 12 years of age and older. Xolegel Gel is a patented
topical formulation of 2% ketoconazole in a translucent, non-greasy gel.
Xolegel Gel applies smoothly and dries clear. With its unique gel
formulation, Xolegel Gel provides patients with a dosing regimen of a once
daily application for only 14 days, thus reducing by approximately 75
percent the number of applications required by other topical antifungal
seborrheic dermatitis therapies. Xolegel Gel was approved by the FDA in
July 2006 and is the first and only FDA-approved prescription gel
formulation of ketoconazole.
Xolegel Duo(TM), available by prescription, also consists of 45 grams of
Xolegel (ketoconazole, USP) Gel, 2% provided in 15 gram tubes, and one 1.7
ounce bottle of Head & Shoulders® (pyrithione zinc 1%) anti-dandruff
shampoo. It is designed to provide a more complete treatment option for
effectively managing seborrheic dermatitis by providing a prescription gel
formulation of ketoconazole for the face and body plus a medicated shampoo
for the scalp in one convenient package. All Xolegel products are covered
under the company's Patient 1st Program. The program allows most
commercial insurance patients to receive their prescription for one $10
copay.
